Dr. Yair Lotan, MD
Claim this profileUniversity of Texas Southwestern Medical Center
Studies Bladder Cancer
Studies Hematuria
12 reported clinical trials
19 drugs studied
Area of expertise
1Bladder Cancer
Stage II
Stage I
2Hematuria
Affiliated Hospitals
Clinical Trials Yair Lotan, MD is currently running
Gemcitabine vs Water Irrigation
for Urothelial Cancer
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical irrigation with sterile water has equivalent efficacy to intravesical chemotherapy in prevention of recurrent bladder cancer following transurethral resection of bladder tumors (TURBT). This study is intended to compare recurrence rates using intravesical gemcitabine (as a pseudo-standard of care) and continuous bladder irrigation with sterile water.
Recruiting2 awards Phase 35 criteria
Optimized Care
for Bladder Cancer
The proposed study is aimed at a comprehensive optimization at-time of radical cystectomy (COARC) intervention that focuses on patient optimization throughout the perioperative continuum, from the pre-operative setting to the post-operative period, among patients undergoing radical cystectomy for bladder cancer. This multi-modal strategy will focus on three phases of care around surgery: the pre-operative, peri-operative, and post-operative phases. The intervention group will focus on multiple areas of patient optimization including remote patient monitoring for the earlier identification of potential complications. The overall study mission is to decrease complication rates after radical cystectomy using this comprehensive approach.
Recruiting1 award N/A1 criteria
More about Yair Lotan, MD
Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Yair Lotan, MD has experience with
- Curcumin
- Cystoscopy With RedPine Flexible Disposable Cystoscope
- Urinalysis
- Placebo
- Placebo
- Preop Intervention And Monitored Recovery
Breakdown of trials Yair Lotan, MD has run
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yair Lotan, MD specialize in?
Yair Lotan, MD focuses on Bladder Cancer and Hematuria. In particular, much of their work with Bladder Cancer has involved Stage II patients, or patients who are Stage I.
Is Yair Lotan, MD currently recruiting for clinical trials?
Yes, Yair Lotan, MD is currently recruiting for 8 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Yair Lotan, MD has studied deeply?
Yes, Yair Lotan, MD has studied treatments such as Curcumin, Cystoscopy with RedPine flexible disposable cystoscope, Urinalysis.
What is the best way to schedule an appointment with Yair Lotan, MD?
Apply for one of the trials that Yair Lotan, MD is conducting.
What is the office address of Yair Lotan, MD?
The office of Yair Lotan, MD is located at: University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States. This is the address for their practice at the University of Texas Southwestern Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.